Case Report: Successful treatment of recurrent COVID-19 with intravenous immunoglobulin in a patient with rituximab-induced B-cell depletion and restoration of Fc-mediated effector functions - Scorecard - MDSpire
Advertisement
Case Report: Successful treatment of recurrent COVID-19 with intravenous immunoglobulin in a patient with rituximab-induced B-cell depletion and restoration of Fc-mediated effector functions
Clinical Scorecard: Case Study: Effective Management of Recurrent COVID-19 in a Rituximab-Treated Patient with B-cell Depletion Using Intravenous Immunoglobulin
At a Glance
Category
Detail
Condition
Key Mechanisms
B-cell depletion leads to impaired antibody production and increased susceptibility to persistent viral infection.
Target Population
Care Setting
Key Highlights
Patient developed prolonged COVID-19 pneumonia after rituximab treatment.
Standard antiviral therapy was ineffective, leading to multiple hospital admissions.
IVIG resulted in rapid clinical improvement.
IVIG restored SARS-CoV-2 specific IgG and immune effector functions.
Guideline-Based Recommendations
Diagnosis
Management
Consider IVIG for patients with persistent COVID-19 and B-cell depletion, if supported by source.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Immunocompromised patients, particularly those on rituximab.
IVIG may provide passive immunity and restore immune functions in B-cell depleted patients.
Investigative report cites internal communications, VAERS data, and CDC case reviews describing myocarditis and pericarditis reports in adolescents and young adults after mRNA COVID-19 vaccination.
